How much funding has Encellin raised?

Encellin has raised $15.8M in total funding, most recently a Series A round.

Who are Encellin's investors?

Encellin's investors include Khosla Ventures, Sv Latam Capital, Y Combinator Continuity Fund.

Where is Encellin headquartered?

Encellin is headquartered in San Francisco, California, United States.

What industry is Encellin in?

Encellin operates in Biotech, Healthcare.

Encellin

Empowering living medicines for endocrine disorders

San Francisco, United States · $15.8M raised

Biotech

Healthcare

Headquarters: San Francisco, California
Employees: 11–50
Business Model: B2B
Website: encellin.com

Total Funding: $15.8M
Last Round: $9.9M Series ADec 2023
Rounds: 2

About

Encellin is a biotechnology company pioneering living medicine platforms to address high unmet clinical needs, starting with endocrine disorders. The company has developed an Encapsulated Cell Replacement Therapy (ENCRT) that enables enclosed cells to function like smart molecular factories, releasing therapeutics when needed — with a lead program targeting hypoglycemia in type 1 diabetes. Encellin's minimally invasive implant platform is designed to deliver years of sophisticated cell-based therapies from a single implant, and the company has demonstrated first-in-human non-fibrotic engraftment of viable encapsulated human islets.

Summary

Encellin is a Biotech company based in San Francisco, United States. It has raised $15.8M in total across 2 rounds, most recently a $9.9M Series A round in Dec 2023. Investors include Khosla Ventures, Sv Latam Capital and Y Combinator Continuity Fund.

LinkedIn X (Twitter)